drugset / Trial / NCT04573153
Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
Phase 2/3
Terminated
100 enrolled
ScandiBio Therapeutics AB
Alanya Allaaddin Keykubat University Hospital · collabBagcilar Training and Research Hospital · collabBakirkoy Dr. Sadi Konuk Research and Training Hospital · collabCanakkale 18 Mart University Health Research and Application Hospital · collabDr. Lutfi Kirdar Kartal Training and Research Hospital · collabIstanbul Medipol University Hospital · collabKanuni Sultan Suleyman Training and Research Hospital · collabMonitorCRO · collabUmraniye Education and Research Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine plus standard therapy. The primary objective is to assess the clinical efficacy of the combination of metabolic cofactors supplementation and hydroxychloroquine in COVID-19 patients.
Timeline
- Start
- 2020-09-21
- Primary completion
- 2022-05-05
- Completion
- 2022-05-05
Outcome
Outcome not reported
Stopped (Enrollment): “Planned enrollment was not fulfilled.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-carnitine | Other / unclassified | — | — |
| Subject | N-acetylcysteine | Small molecule | — | — |
| Subject | Nicotinamide riboside | Small molecule | — | — |
| Subject | Serine | Unknown | — | — |
| Background | Hydroxychloroquine | Small molecule | — | — |